You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Details for Patent: 7,214,696


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,214,696
Title:Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Abstract: Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods, screening methods, as well as specific transthyretin stabilizing compounds are disclosed.
Inventor(s): Kelly; Jeffery W. (LaJolla, CA), Sekijima; Yoshiki (Matsumoto, JP)
Assignee: The Scripps Research Institute (La Jolla, CA)
Application Number:11/256,026
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,214,696
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,214,696

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Foldrx Pharms VYNDAMAX tafamidis CAPSULE;ORAL 212161-001 May 3, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) ⤷  Try a Trial
Foldrx Pharms VYNDAQEL tafamidis meglumine CAPSULE;ORAL 211996-001 May 3, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,214,696

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 405840 ⤷  Try a Trial
Austria 524741 ⤷  Try a Trial
Australia 2003303196 ⤷  Try a Trial
Australia 2010201263 ⤷  Try a Trial
Brazil 0317463 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.